Autolus Therapeutics plc (AUTL)

NMS – Цена в реальном времени. Валюта: USD

1.60

+0.02 (1.27%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.60

0.00 (0.00%)

До открытия: May 13, 2026, 4:43 AM EDT

05.05.2026

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14, 2026.

29.04.2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026 Autolus reiterates full year 2026 AUCATZYL® net product revenue of $120 million to $135 million, up from $74 million in 2025, as well as an anticipated shift to positive gross margin in 2026 Clinical development programs are on track and include CATULUS, a pivotal Phase 2 trial in pediatric relapsed/refractory acute lymphoblastic leukemia; LUMINA, a pivotal Phase 2 trial in lupus nephritis; and BOBCAT, an exploratory Phase 1 trial in progressive multiple sclerosis LONDON and GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses.

21.04.2026

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company's 2025 Inducement Plan.

08.04.2026

Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript

07.04.2026

Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in two upcoming investor conferences.

27.03.2026

Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts

Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues and a shift to positive gross margin, with AUTL's cash runway projected into Q4 2027. Key catalysts include pediatric ALL Phase 2 data (2027) and initial MS autoimmune data (late 2026), both with significant upside potential.

27.03.2026

Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

29.04.2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

21.04.2026

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

27.03.2026

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluation Autolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026 Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in progressive MS anticipated by year-end 2026 Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces its operational and financial results for the fourth quarter and full year ended December 31, 2025.

04.02.2026

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company's 2025 Inducement Plan.

Autolus Therapeutics plc (AUTL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Autolus Therapeutics plc (AUTL)

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts

Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts

Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Autolus Therapeutics plc (AUTL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Autolus Therapeutics plc (AUTL)

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts

Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts

Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)